Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)

Ngumah et al., NCT04439071, FITE19, NCT04439071, Jun 2023
Late treatmentRCT · NCT04439071 · 189 patients · multinational
Emvododstat for COVID-19
FITE19 Ngumah et al. NCT04439071 · June 2023
Outcome
Improvement
Relative Risk · 95% CI
Higher mortality and ventilation
Not statistically significant · p = 0.16 (mortality) and p = 0.31 (ventilation)
RCT 189 hospitalized patients showing higher mortality with emvododstat (PTC299), without statistical significance.
OutcomeImprovementEffect · pTreatmentControl
risk of death 132.3% higher · RR 2.32 · p = 0.16 132.3% higherRR 2.32p = 0.16 9 of 92 (9.8%) 4 of 95 (4.2%) treatment 9 of 92 (9.8%), control 4 of 95 (4.2%)day 60
risk of death 54.9% higher · RR 1.55 · p = 0.53 54.9% higherRR 1.55p = 0.53 6 of 92 (6.5%) 4 of 95 (4.2%) treatment 6 of 92 (6.5%), control 4 of 95 (4.2%)day 28
risk of mechanical ventilation 47.0% higher · RR 1.47 · p = 0.31 47.0% higherRR 1.47p = 0.31 16 of 94 (17.0%) 11 of 95 (11.6%) treatment 16 of 94 (17.0%), control 11 of 95 (11.6%)day 28

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Ngumah et al., 26 Jun 2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT04439071 (history) (FITE19). Contact: medinfo@ptcbio.com.
Late treatment
is less effective